At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed incurable adult primary malignant brain tumor
- ✓Evidence of progressive or recurrent tumor by MRI scan within 2 weeks prior to study entry
- ✓Must have received and failed standard therapy
- ✓Tumor must be at least 5 mm
- ✕Brain stem tumors
- ✕Uncontrolled hypertension
- ✕History of congestive heart failure or chronic heart failure
- ✕Cardiovascular conditions that contraindicate high dosages of sodium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Malignant Brain Tumors. Completed, enrolled 40 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for adults with primary malignant brain tumors that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with primary malignant brain tumors that have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with primary malignant brain tumors that have not responded to standard therapy.
Study Details
Timeline
Interventions
Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.